87623 Infectious agent detection by nucleic acid (DNA or RNA); Human Papillomavirus (HPV), low-risk types (eg, 6, 11, 42, 43, 44)

Name of the Procedure:

Infectious agent detection by nucleic acid (DNA or RNA); Human Papillomavirus (HPV), low-risk types (e.g., 6, 11, 42, 43, 44)

Summary

This procedure involves testing for the presence of low-risk types of Human Papillomavirus (HPV) by detecting its DNA or RNA. It is a diagnostic test that helps identify specific strains of HPV known to cause benign conditions, such as genital warts.

Purpose

The procedure addresses the need to diagnose infections caused by low-risk HPV types. It aims to confirm the presence of HPV strains 6, 11, 42, 43, or 44, which are usually associated with benign lesions and genital warts, rather than cancerous growths.

Indications

• Patients presenting with genital warts or other lesions suggestive of a low-risk HPV infection.
• Individuals with risk factors such as multiple sexual partners or a history of sexually transmitted infections.
• Routine screening in certain patient populations as recommended by a healthcare provider.

Preparation

• No special preparation is typically required.
• Patients may be advised to avoid sexual activity for 24-48 hours before the test.
• Women may be asked to avoid scheduling the test during menstruation.

Procedure Description

1. A healthcare provider collects a sample from the affected area, usually using a swab or brush.
2. The sample is sent to a laboratory specialized in molecular diagnostics.
3. In the lab, nucleic acid extraction is performed to isolate DNA or RNA from the HPV virus.
4. Specific molecular techniques, such as PCR (Polymerase Chain Reaction), are used to amplify and detect the genetic material of HPV types 6, 11, 42, 43, or 44.
5. Results are analyzed and reported back to the healthcare provider.

Duration

The sample collection process typically takes a few minutes. Laboratory analysis may take several days to a week.

Setting

The sample collection can be performed in a doctor's office, clinic, or outpatient setting. The laboratory analysis is conducted in a specialized molecular diagnostics lab.

Personnel

• Physician, nurse, or trained technician for sample collection.
• Medical laboratory technicians and molecular biologists for sample analysis.

Risks and Complications

• Minimal risks associated with sample collection, such as mild discomfort or local irritation.
• Rare chance of incorrect results due to sample contamination or technical error.

Benefits

• Accurate identification of low-risk HPV types.
• Helps in the appropriate management and treatment of benign lesions and genital warts.
• Early identification can lead to better patient outcomes and reassurance.

Recovery

• No significant recovery time required.
• Patients can return to their normal activities immediately after sample collection.
• Follow-up appointments may be scheduled to discuss results and treatment plans if necessary.

Alternatives

• Clinical examination and visual diagnosis of warts and lesions.
• Other biomarkers or tests, such as Pap smear tests, although they are typically more geared towards detecting high-risk HPV types.

Patient Experience

• Patients may feel mild discomfort during sample collection, but the procedure is generally quick and well-tolerated.
• Any pain or irritation is usually minimal and short-lived.
• Anxiety related to awaiting test results can be managed through counseling and support from healthcare providers.